Paul A. Mahon Sells 11,000 Shares of United Therapeutics Co. (NASDAQ:UTHR) Stock

United Therapeutics Co. (NASDAQ:UTHR) EVP Paul A. Mahon sold 11,000 shares of the business’s stock in a transaction dated Thursday, April 3rd. The shares were sold at an average price of $306.18, for a total value of $3,367,980.00. Following the completion of the sale, the executive vice president now owns 36,781 shares in the company, valued at approximately $11,261,606.58. This trade represents a 23.02 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

United Therapeutics Stock Up 0.2 %

Shares of UTHR stock traded up $0.68 during trading on Monday, reaching $293.14. 68,546 shares of the company’s stock were exchanged, compared to its average volume of 449,113. United Therapeutics Co. has a twelve month low of $230.39 and a twelve month high of $417.82. The firm’s fifty day moving average price is $333.78 and its 200-day moving average price is $354.54. The stock has a market capitalization of $13.17 billion, a PE ratio of 12.86, a PEG ratio of 0.97 and a beta of 0.63.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, February 26th. The biotechnology company reported $6.19 EPS for the quarter, beating the consensus estimate of $6.10 by $0.09. The firm had revenue of $735.90 million for the quarter, compared to the consensus estimate of $734.74 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. During the same period in the previous year, the company earned $4.36 earnings per share. As a group, analysts anticipate that United Therapeutics Co. will post 24.48 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have commented on UTHR. StockNews.com cut United Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Thursday, February 27th. UBS Group boosted their price objective on shares of United Therapeutics from $415.00 to $475.00 and gave the stock a “buy” rating in a research report on Wednesday, January 8th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $425.00 target price on shares of United Therapeutics in a research report on Thursday, February 27th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and ten have assigned a buy rating to the stock. Based on data from MarketBeat.com, United Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $388.25.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. Newbridge Financial Services Group Inc. acquired a new position in shares of United Therapeutics in the fourth quarter valued at approximately $25,000. Dunhill Financial LLC lifted its position in United Therapeutics by 100.0% during the fourth quarter. Dunhill Financial LLC now owns 100 shares of the biotechnology company’s stock worth $35,000 after purchasing an additional 50 shares during the period. State of Wyoming acquired a new stake in shares of United Therapeutics during the 4th quarter worth approximately $62,000. Millstone Evans Group LLC bought a new position in shares of United Therapeutics in the 4th quarter valued at $67,000. Finally, MassMutual Private Wealth & Trust FSB raised its stake in United Therapeutics by 31.9% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biotechnology company’s stock worth $85,000 after acquiring an additional 58 shares in the last quarter. 94.08% of the stock is owned by institutional investors.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.